Table 1

Baseline characteristics of the study population

Overall population
(n=54)
Cohort-1
(n=27)
Cohort-2
(n=27)
Sex, n(%)
Male 34 (63)14 (52)20 (74)
Female 20 (37)13 (48)7 (26)
Median age at treatment initiation, years 55 (range 19–75)57 (range 20–70)47 (range 19–75)
ECOG performance status, n(%)
0 27 (50)20 (74)7 (26)
1 22 (41)6 (22)16 (59)
2 5 (9)1 (4)4 (15)
Diagnosis, n(%)
Primary diagnosis of grade IV glioma 37 (69)18 (67)19 (70)
Primary diagnosis of lower-grade glioma with evolution to high-grade glioma 17 (31)9 (33)8 (30)
Molecular profile, n(%)
IDH1/2 mutation
  Mutant 10 (19)5 (19)5 (19)
  Wild-type 34 (63)20 (74)14 (52)
  Unknown 10 (19)2 (7)8 (30)
MGMT promotor
  Methylated 6 (11)3 (11)3 (11)
  Unmethylated 14 (26)8 (30)6 (22)
  Unknown 34 (63)16 (59)18 (67)
1 p/19q codeletion
  Yes 4 (7)1 (4)3 (11)
  No 19 (35)11 (41)8 (30)
  Unknown 31 (57)15 (56)16 (59)
Use of oral corticosteroid therapy at treatment initiation, n(%) 31 (57)4 (15)27 (100)
Median daily dose of methylprednisolone at baseline 8 mg32 mg
Prior therapy for primary diagnosis of glioma, n(%)
Primary surgery for diagnosis
  Resection 47 (87)24 (89)23 (85)
  Biopsy 7 (13)3 (11)4 (15)
Primary therapeutic strategy
  Resection/biopsy only 7 (13)3 (11)4 (15)
  Radiation therapy only 1 (2)0 (0)1 (4)
  Chemotherapy only 1 (2)0 (0)1 (4)
  Surgery+chemotherapy only 1 (2)1 (4)0 (0)
  Surgery+radiation therapy only 3 (6)2 (7)1 (4)
  Surgery+radiation therapy +chemotherapy (sequential)1 (2)0 (0)1 (4)
  Surgery+concomitant radiation therapy/TMZ+adjuvant TMZ 40 (74)21 (78)19 (70)
Prior therapy for recurrent GB, n(%) 39 (72)20 (74)19 (70)
Surgery 33 (61)18 (33)15 (56)
  Median no of surgeries 1 (range 1–4)1 (range 1–2)1 (range 1–4)
Radiation therapy 11 (20)6 (22)5 (19)
Systemic therapy 33 (61)16 (59)17 (63)
  Median no of lines of systemic therapy 1 (range 1–4)1 (range 1–4)1 (range 1–3)
  • 1 p/19q codeletion: deletion of short arm of chromosome one and long arm of chromosome 19.

  • ECOG, Eastern Cooperative Oncology Group; GB, glioblastoma; IDH, isocitrate dehydrogenase; MGMT, O-6-methylguanine-DNA methyltransferase; TMZ, temozolomide.